RxDoctor Payments Data

Elvin Rivera, MD

Cardiovascular Disease · San Juan, PRNPI 1245283431

Payments from drug & device makers

$1,206in general payments, 2019–2025

Across 53 payments — averaging $22.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$960
  • PBG Puerto Rico LLC$102
  • Johnson & Johnson$28
  • Boehringer Ingelheim$25
  • Edwards Lifesciences$24
  • AstraZeneca$23
  • plus $44 from 2 others

What the payments were for

  • Food & beverage$1,206100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)42$960
PBG Puerto Rico LLC5$102
Johnson & Johnson1$28
Boehringer Ingelheim1$25
Edwards Lifesciences1$24
AstraZeneca1$23
Pfizer Pharmaceuticals LLC1$22
Novartis1$22

How this compares

$1,206 in reported general payments places this provider in the 30th percentile of 267 cardiovascular disease providers in Puerto Rico.

See all cardiovascular disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$13,497
Medicare patients
39
Services billed
193

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban95$64,340
XareltoRivaroxaban34$29,814
JanuviaSitagliptin Phosphate36$29,457
BrilintaTicagrelor38$24,826
OzempicSemaglutide18$16,821
FarxigaDapagliflozin Propanediol21$13,548
Metoprolol Succinate186$2,673
SynthroidLevothyroxine Sodium31$2,258
Candesartan-HydrochlorothiazidCandesartan/Hydrochlorothiazid11$2,069
Losartan Potassium151$1,769
ClopidogrelClopidogrel Bisulfate89$1,547
Amiodarone Hcl35$1,223
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide58$1,156
Ranolazine ErRanolazine22$924
Irbesartan31$894

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta, Farxiga$23$38,37459 claims
Johnson & JohnsonXarelto$28$29,81434 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 267 cardiovascular disease providers in Puerto Rico.

Other cardiovascular disease in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →